One of the contributory causes to biotech bubbles seems to be a
collective amnesia on the part of investors regarding the fact that not
every drug launched for an indication is going to succeed. Even in
underserved indications like lung cancer, there are winners and losers
and competitive differentiation is an important part of long-term
success.
In the case of Clovis Oncology (NASDAQ:CLVS), I think investors are right to be concerned about the potential competitive pressures from AstraZeneca (NYSE:AZN) and Tesaro (NASDAQ:TSRO)
among others, but I also think the market is underestimating the value
of the company's lead drug candidates for lung and ovarian cancer.
Read the full article here:
Competition Will Be Tough, But Clovis Oncology Has Legitimate Compounds
No comments:
Post a Comment